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Abstract
Importance—Sentinel lymph node (SLN) surgery provides reliable nodal staging information
with less morbidity than axillary lymph node dissection (ALND) for clinically node-negative
(cN0) breast cancer patients. The application of SLN surgery for staging the axilla following
chemotherapy for women who initially had node-positive breast cancer (cN1) is unclear because
of high false negative results reported in previous studies.
Objective—To determine the false negative rate (FNR) for SLN surgery following chemotherapy
in patients initially presenting with biopsy-proven node-positive breast cancer.
Design, Setting, and Patients—The ACOSOG Z1071 trial enrolled women with clinical T0–
4 N1–2, M0 breast cancer who received neoadjuvant chemotherapy. Following chemotherapy,
patients underwent both SLN surgery and ALND. SLN surgery using both blue dye and a
radiolabeled colloid mapping agent was encouraged.
Main Outcome Measure—The primary endpoint was the FNR of SLN surgery after
chemotherapy in women who presented with cN1 disease. We examined the likelihood that the
FNR in those with 2 or more SLNs examined was greater than 10%, the rate expected for women
undergoing SLN surgery who present with clinically node-negative disease.
Results—Seven hundred fifty-six patients were enrolled from 136 institutions. Of 663 evaluable
patients with cN1 disease, 649 underwent chemotherapy followed by both SLN surgery and
ALND. A SLN could not be identified in 46 patients (7.1%). Only one SLN was excised in 78
patients (12.0%). Of the remaining 525 patients with 2 or more SLNs removed, no cancer was
identified in the axillary lymph nodes of 215 patients yielding a pathological complete nodal
response of 41.0% (95% CI: 36.7%–45.3%). In 39 patients, cancer was not identified in the SLNs
but was found in lymph nodes obtained with ALND resulting in a FNR of 12.6% (90% Bayesian
Credible Interval, 9.85%–16.05%).
Conclusions and Relevance—Among women with cN1 breast cancer receiving neoadjuvant
chemotherapy who had 2 or more SLNs examined, the FNR was not found to be 10% or less.
Given this FNR threshold, changes in approach and patient selection that result in greater
sensitivity would be necessary to support the use of SLN surgery as an alternative to ALND.
Trial Registration—clinicaltrials.gov; trial identifier NCT00881361.
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Axillary lymph node status is an important prognostic factor in breast cancer and is used to
guide local, regional, and systemic treatment decisions. In patients with large primary
tumors or involved lymph nodes, chemotherapy is often delivered preoperatively in order to
assess response to chemotherapy and to increase the likelihood of breast conserving surgery.
Residual axillary nodal disease is found in only 50–60% of breast cancer patients initially
presenting with node-positive disease (cN1) who receive neoadjuvant chemotherapy.
Accurate determination of axillary involvement after chemotherapy is important; however
removing all axillary nodes to assess for residual nodal disease subjects many patients to the
morbidity of surgery while potentially only a subset will benefit.
To avoid the complications associated with axillary lymph node dissection (ALND), it is
preferable to identify nodal disease with the less invasive SLN procedure which results in
less morbidity.1 SLN surgery is considered reliable for identifying axillary nodal disease in
women initially presenting without clinically evident nodes (cN0). False negative results can
occur when the SLNs do not contain cancer, but cancer is found in nodes obtained on
completion ALND. False negative rates for SLN surgery range from 0% to 20%2–9 after
chemotherapy in cN0 patients, with a meta-analysis reporting a FNR of 12%.10
Subsequently, investigators from the National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-27 trial including both cN0 and cN1 disease and reported a SLN FNR of 10.7%
after chemotherapy9. However, the utility of SLN surgery following neoadjuvant
chemotherapy for cN1 patients has been questioned, as the only available data has been from
small series reporting FNRs ranging from 7% to 29.6%. Anthracyclines and taxane-based
chemotherapy regimens have been shown to eradicate nodal disease in approximately 30–
40% of patients.11 These patients would not benefit from ALND but may suffer
complications of the procedure. In order to apply SLN surgery in this setting, an acceptably
low FNR must be demonstrated. ACOSOG Z1071 was designed to determine the FNR of
SLN surgery after chemotherapy in women initially presenting with axillary node-positive
disease.
PATIENTS AND METHODS
The ACOSOG Z1071 trial was a phase II clinical trial designed to determine the FNR for
SLN surgery performed after neoadjuvant chemotherapy in women presenting with
pathologically proven node-positive breast cancer. The institutional review boards of all
participating institutions approved this study, and written informed consent was obtained
from each patient before study entry.
Eligibility and Exclusion Criteria
We enrolled women older than 18 years of age who 1) had histologically proven clinical
stage T0–4, N1–2, M0 primary invasive breast cancer according to the American Joint
Committee on Cancer (AJCC) 6th edition staging system (Table 1); 2) had an Eastern
Cooperative Oncology Group performance status of 0 or 1; 3) had completed or were
planning to undergo neoadjuvant chemotherapy (the regimen was at the discretion of the
patient’s medical team); and 4) had pre-chemotherapy axillary nodal disease confirmed by
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fine-needle aspiration or core needle biopsy. Patients with a history of prior ipsilateral
axillary surgery, prior SLN surgery, or excisional lymph node biopsy for pathologic
confirmation of axillary status were excluded. Patients were staged as cN1 according to the
AJCC staging system: disease in movable axillary lymph nodes or cN2: disease in fixed or
matted axillary lymph nodes.
Surgical Intervention and Nodal Evaluation
Breast cancer surgery was performed within 84 days after completion of chemotherapy.
After chemotherapy and within 4 weeks before surgery, patients underwent a physical
examination and axillary ultrasonography. At surgery, patients had appropriate treatment of
the primary tumor and underwent SLN surgery and then ALND.
SLN surgery allows surgeons to identify the first lymph node(s) along the lymphatic
drainage pathway from the primary tumor in the breast to the axillary lymph node basin. It
requires injection of a radiolabelled colloid, blue dye, or a combination (“mapping agents”)
in the breast which is taken up by the breast lymphatics as they travel to the axillary nodes.
If radiolabelled colloid is used, a gamma probe identifies radioactivity in the lymph nodes in
the axilla. If blue dye is used, blue stained lymphatic channels visualized during surgery are
followed to lymph nodes where the blue dye accumulates. Additionally, the axilla is
carefully palpated and any palpably abnormal lymph nodes are identified. Lymph nodes that
are radioactive, blue, or palpably abnormal are considered SLNs and are resected and
submitted for pathological analysis.
In ACOSOG Z1071, SLN mapping with both blue dye (isosulfan blue or methylene blue)
and radiolabeled colloid mapping agents was recommended to maximize the likelihood of
SLN identification and to minimize the possibility of missing SLNs which could result in a
false negative event. All SLNs were excised and submitted before the ALND was
performed. The protocol required that at least 2 SLNs be resected. Each SLN was examined
with hematoxylin-eosin staining and positive SLNs were defined as those with metastases
larger than 0.2 mm as per the AJCC 6th edition staging system. Nodes removed at ALND
were evaluated by hematoxylin-eosin staining using institutional standard operating
procedures.
Statistical Analysis
This study was designed to evaluate the primary and secondary endpoints in the cN1 cohort
independently of that in the cN2 cohort. The primary aim was to examine the FNR of SLN
surgery after chemotherapy when at least 2 SLNs are excised. A secondary aim was to
determine the pathologic complete nodal response (pCR) rate where a nodal pCR is the
pathologic finding of negative nodes (pN0) on the basis of SLN surgery and ALND.
In the cN1 cohort, a Bayesian approach was chosen to determine whether the FNR was
greater than 10%,,12,13 the rate expected for SLN surgery in women who initially present
with clinically negative axillary lymph nodes. Assuming the number of women with
negative SLN results after chemotherapy, X, has a binomial (n, θ) distribution, where θ is
the probability of a false-negative SLN result and its prior distribution is a uniform (0,1)
distribution, then the posterior distribution for θ is a Beta(x+1,n−x+1) distribution. The SLN
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FNR is considered too high if there is a greater than 95% chance that the FNR is greater than
10%. With a sample size of 300 patients, this translated to concluding that the SLN FNR is
greater than 10% if 39 or more patients are found to have a false negative SLN finding.
Operating characteristics of this design based on 10,000 simulations were such that the
probability of concluding that that the true FNR is larger than 10% is 0.053 when the true
FNR is 10% and 0.852 when the true FNR is 15%. A two-sided 90% Bayesian credible
interval (BCI) for the true FNR was constructed.
In an exploratory analysis, Fisher exact tests and multivariable logistic regression modeling
with Score statistics and likelihood ratio tests were used on the likelihood of a false-negative
SLN finding. All tests were 2-sided.
In the cN2 cohort, it was anticipated that 43 women with cN2 disease would be enrolled
who would have at least 2 SLNs examined after chemotherapy and have residual nodal
disease. However, only 14 such women were enrolled and as such a 95% binomial
confidential interval for the FNR in this patient population was constructed.
A 95% binomial confidence interval was constructed for the pathologic complete response
rate.
The database used for these analyses was locked May 1, 2013. Statistical analyses were
carried out using SAS 9.2 (SAS Institute Inc., Cary, NC). The trial was registered on
clinicaltrials.gov with trial identifier NCT00881361.
RESULTS
Seven hundred fifty-six women with clinical stage T0–4, N1–2, M0 breast cancer who
received neoadjuvant chemotherapy were enrolled between July 2009 and June 2011 from
136 institutions. Twenty-one women were ineligible, and 34 patients withdrew from the
study before surgery (Figure 1). Patient, disease, and chemotherapy characteristics for the
remaining 701 women are presented in Table 1 by clinical nodal stage prior to
chemotherapy. A total of 663 women had cN1 disease, and 38 had cN2 disease. The
chemotherapy regimens varied, but the majority included an anthracycline and taxane
(74.6%, see Table 1). The duration of chemotherapy varied from 1 month to 7 months
(median, 4 months). Fifty-nine patients (8.4%) discontinued chemotherapy early because of
disease progression (7 patients; 1.0%); intolerable adverse effects (42 patients; 6.0 %);
refusal (5 patients; 0.7%); lack of tumor response (3 patients; 0.4%); physician discretion (1
patient; 0.1%); or desire for alternative therapy (1 patient; 0.1%).
After completion of chemotherapy, clinical examination of the axilla revealed no palpable
lymphadenopathy in 582 patients (83.0%), palpable nodes in 84 patients (12.0%), and fixed
or matted nodes in 4 patients (0.6%). Results of palpation were not reported in 31 patients
(4.4%).
Of the 701 evaluable women, 2 women (0.3%) underwent SLN surgery only; 687 women
(98.0%) underwent both SLN surgery and ALND; and 12 (1.7%) underwent ALND only.
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Of the 689 women who underwent SLN surgery, 28 (4.1%) had mapping performed with
blue dye only, 116 (16.8%) had mapping with radiolabeled colloid only, and 545 (79.1%)
had mapping with both blue dye and radiolabeled colloid.
At least 1 SLN was detected in 639 (92.7%; 95% CI, 90.5%–94.6%) of these 689 women.
Rates of detection of at least 1 SLN were 92.9% (n=605; 95% CI, 90.7%–94.8%) in the 651
patients with cN1 disease and 89.5% (n=34; 95% CI, 75.2%–97.1%) in the 38 patients with
cN2 disease.
FNR in Women With cN1 Disease and at Least 2 SLNs Examined
There were 525 patients with cN1 disease who had at least 2 SLNs excised and went on to
complete ALND. Pathologic examination of the SLNs and nodes removed on ALND found
no residual nodal disease in 215 of these patients yielding a nodal pathological complete
response rate of 41.0% (95% CI: 36.7%–45.3%). Among the remaining 310 patients,
residual nodal disease was confined to the SLNs in 108 patients (20.6%); confined to the
nodes removed on ALND in 39 patients (7.4%); and present in nodes from both procedures
in 163 patients (31.1%). Thus, 39 of the 310 patients with residual nodal disease had a false-
negative SLN finding, a FNR of 12.6% (90% Bayesian credibility interval: 9.85%–16.05%).
Bivariable analyses found that the likelihood of a false-negative SLN finding was
significantly decreased when the mapping was performed with the combination of blue dye
and radiolabeled colloid (P = .052; FNR: 10.8% vs. 20.3%) and by examination of at least 3
SLNs (P = .007: 9.1% vs. 21.1%) (Table 3). Multivariable logistic modeling revealed that,
once the number of SLNs examined (2 vs. 3 or more) was accounted for, no other factors
made a significant contribution in explaining the variability in likelihood of a false-negative
SLN finding.
Women With cN2 Disease and at Least 2 SLNs Examined
Among the 26 women with cN2 disease with at least 2 SLNs excised followed by ALND;
12 patients had no residual nodal disease found resulting in a pathological complete
response rate of 46.1% (95%CI: 26.6–66.6%). Fourteen patients had residual nodal disease
either confined to the SLNs (6 patients) or present in both SLNs and nodes removed on
ALND (8 patients) yielding a FNR of 0% (95%CI: 0–23.2%).
DISCUSSION
This multicenter trial showed that the FNR of SLN surgery after neoadjuvant chemotherapy
in patients with cN1 breast cancer and at least 2 SLNs identified at the time of surgery was
12.6%,. higher than the prespecified threshold of 10%. This threshold was considered
acceptable based on prior studies of SLN surgery reporting a 10–12% FNR following
chemotherapy in cN0 patients10.
Although our findings suggest that one cannot reliably detect all axillary lymph node
metastases in cN1 breast cancer patients following chemotherapy by SLN procedures, we
did identify important factors influencing the likelihood of a false-negative SLN. The FNR
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was significantly lower when a dual-agent mapping technique (10.8%) relative to single
agent mapping (20.3%, p=0.05) technique was utilized. The FNR with dual agent mapping
reported in this study is similar to the findings from the NSABP B-27 trial where
investigators reported a FNR of 9.3% with dual agent mapping in predominantly cN0 but
some cN1 patients.13 After chemotherapy, the axilla often has more fibrosis, making
evaluation of lymphatic drainage and surgical dissection more challenging. Using two
mapping agents with different molecular sizes and transit times is an important surgical
standard that should be adhered to for SLN surgery after chemotherapy.
Our study also found that the FNR is lower when 3 or more SLNs are evaluated relative to
only 2 SLNs being evaluated. In the NSABP B-27 study this issue was not addressed. The
NSABP B-32 trial, in which SLN surgery was performed before any chemotherapy, reported
that there was a significant decrease in the FNR as more SLNs were resected: 18% with 1
SLN resected, 10% with 2 SLNs resected, and 7% with 3 SLNs resected.14 Similarly, Hunt
et al. showed that removal of fewer than 2 SLNs was associated with a higher FNR in
patients with clinically node-negative disease undergoing SLN surgery after
chemotherapy.15 As the accuracy of any sampling test is dependent on the amount of
material sampled, these results are not surprising.
A shortcoming of this study is that patients who had node-positive disease prior to planned
chemotherapy could be enrolled before, during, or after chemotherapy regardless of type or
length of therapy, reason for discontinuing chemotherapy, or nodal response after
chemotherapy (based on physical examination or axillary ultrasound). More appropriate
candidates for SLN surgery may have been patients with the highest likelihood of nodal
response and lowest likelihood of residual nodal disease and those with normalization of
nodal architecture on ultrasonography. As such, patients with significant residual nodal
disease or poor clinical or radiologic response to chemotherapy are most likely poor
candidates for SLN surgery. Until further data are available, we recommend that SLN
surgery after chemotherapy not be performed in patients with clinically evident residual
nodal disease or poor response to chemotherapy.
In summary, the ACOSOG Z1071 trial found that among women presenting with cN1 breast
cancer who received chemotherapy and had 2 or more SLNs examined, the FNR was 12.6%
(90% BCI, 9.85%–16.05%). Both the use of dual mapping agents and recovery of more than
2 SLNs were associated with a lower likelihood of false-negative SLN findings.
CONCLUSION
Among women with cN1 breast cancer receiving neoadjuvant chemotherapy who had 2 or
more SLNs examined, the FNR with SLN surgery exceeded the pre-specified threshold of
10%. Given this acceptability threshold, changes in approach and patient selection that result
in greater sensitivity would be necessary to support use of SLN surgery as an alternative to
ALND in this patient population.
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Table 1
Patient and Treatment Characteristics by Clinical Nodal Staging at Presentation*
Characteristic cN1 (n = 663) cN2 (n = 38)
Age, years
 18–39 120 (18.1) 4 (10.5)
 40–49 213 (32.1) 15 (39.5)
 50–59 197 (29.7) 10 (26.3)
 60–69 112 (16.9) 5 (13.2)
 70+ 21 (3.2) 4 (10.5)
Race (patient reported)
 White 537 (81.0) 28 (73.7)
 Black or African American 95 (14.3) 5 (13.2)
 Asian 18 (2.7) 1 (2.6)
 American Indian or Alaska Native 2 (0.3) 1 (2.6)
 Not reported 11 (1.6) 3 (7.9)
Body mass index
 Underweight/normal (BMI < 25.0) 187 (28.2) 9 (23.7)
 Overweight/obese (BMI >= 25.0) 475 (71.6) 28 (73.7)
 Unknown 1 (0.2) 1 (2.6)
Eastern Cooperative Oncology Group performance status
 0 536 (80.8) 26 (68.4)
 1 127 (19.2) 12 (31.6)
Smoking status
 Current 81 (12.2) 4 (10.5)
 Never 451 (68.0) 30 (78.9)
 Past 104 (15.7) 4 (10.5)
 Not stated 27 (4.1) 0
Concurrent conditions
 Diabetes 53 (8.0) 4 (10.5)
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Characteristic cN1 (n = 663) cN2 (n = 38)
 Peripheral vascular disease 3 (0.4) 1 (2.6)
 Arthritis 44 (6.6) 4 (10.5)
 Cardiac disease 169 (25.5) 10 (26.3)
Clinical T category at diagnosis**
 T0/Tis 5 (0.8) 2 (5.3)
 T1 86 (13.0) 5 (13.2)
 T2 372*** (56.1) 4 (10.5)
 T3 175 (26.4) 13 (34.2)
 T4 25 (3.8) 10 (26.2)
Approximated subtype
 HER2-positive 197 (29.7) 12 (31.6)
 Hormone receptor positive/HER2-negative 301 (45.4) 14 (36.8)
 Triple receptor negative 156 (23.5) 10 (26.3)
 Insufficient information to classify/no invasive breast tumor/prior breast surgery 9 (1.4) 2 (5.3)
Tumor histology
 Invasive ductal carcinoma (IDC) 590 (89.0) 30 (79.0)
 Invasive lobular carcinoma (ILC) 37 (5.6) 1 (2.6)
 Mix of IDC and ILC 11 (1.7) 0
 Invasive carcinoma, other 22 (3.0) 5 (13.2)
 DCIS 2 (0.3) 0
 no breast disease (stage T0 – no identifiable primary in the breast) 3 (0.5) 2 (5.3)
Type of axillary lymph node biopsy
 Fine needle aspiration 259 (39.1) 13 (34.2)
 Core needle biopsy 404 (60.9) 25 (65.8)
Clip placed in axilla
 Yes 214 (32.3) 16 (42.1)
 No 448 (67.6) 22 (57.9)
 Not stated 1 (0.2) 0
Neoadjuvant chemotherapy regimen
 Contained an anthracycline and a taxane 499 (75.3) 24 (63.2)
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Characteristic cN1 (n = 663) cN2 (n = 38)
 Contained an anthracycline but not a taxane 41 (6.2) 3 (7.9)
 Contained a taxane but not an anthracycline 112 (16.9) 10 (26.3)
 Contained neither an anthracycline nor a taxane 11 (1.7) 1 (2.6)
Reason chemotherapy discontinued
 Chemotherapy completed (not discontinued) 609 (91.9) 33 (86.8)
 Disease progression 6 (0.9) 1 (2.6)
 Intolerable adverse effects 38 (5.7) 4 (10.5)
 Refusal 5 (0.7) 0
 Lack of tumor response 3 (0.4) 0
 Physician discretion 1 (0.2) 0
 Desire for alternative therapy 1 (0.2) 0
Findings on clinical examination of axilla after chemotherapy
 No palpable adenopathy 556 (83.9) 26 (68.4)
 Palpable lymph nodes 76 (11.5) 8 (21.1)
 Fixed or matted lymph nodes 2 (0.3) 2 (5.3)
 Not reported 29 (4.4) 2 (5.3)
Type of breast surgery after chemotherapy
 Partial mastectomy 266 (40.1) 11 (28.9)
 Total mastectomy 395 (59.6) 25 (65.8)
 None 2 (0.3) 2 (5.3)
Type of axillary surgery
 SLN surgery only 2 (0.3) 0
 SLN attempted but no SLN identified; ALND 46 (6.9) 4 (10.5)
 SLN with SLN identified; ALND 603 (91.0) 34 (89.5)
 ALND 12 (1.8) 0
***
one patient underwent a partial mastectomy prior to chemotherapy
*
cN1: disease in movable axillary lymph nodes; cN2: disease in fixed or matted axillary lymph nodes.
**
cT0: no evidence of disease in the breast; cT1: breast tumor size ≤ 2 cm; cT2: breast tumor more than 2 cm but at most 5 cm; cT3: breast tumor
size > 5 cm; cT4: tumor extension to chest wall or skin.
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Abbreviations: ALND, axillary lymph node dissection; BMI, body mass index; SLN, sentinel lymph node.
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Table 2
Details of SLN Surgery
Variable cN1 (n = 651) cN2 (n = 38)
Mapping agent used
 Blue dye 25 (3.8) 3 (7.9)
 Radiolabelled colloid 109 (16.7) 7 (18.4)
 Both 517 (79.4) 28 (73.7)
Timing of radiolabelled colloid injection
 Day before surgery 160 (24.6) 5 (13.2)
 Morning of surgery 466 (71.6) 30 (78.9)
 Not used 25 (3.8) 3 (7.9)
Injection site(s)
 Subareolar/periareolar 404 (62.1) 31 (81.6)
 Peritumoral 56 (8.6) 1 (2.6)
 Intradermal 17 (2.6) 2 (5.3)
 Multiple sites 147 (22.6) 2 (5.3)
 Not specified 27 (4.1) 2 (5.3)
Number of SLNs examined
 0 46 (7.1) 4 (10.5)
 1 78 (12.0) 8 (21.1)
 2 155 (23.8) 10 (26.3)
 3 148 (22.7) 6 (15.8)
 4 90 (13.8) 5 (13.2)
 5+ 134 (20.6) 5 (13.2)
Abbreviation: SLN, sentinel lymph node.
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Table 3
Factors Affecting the Likelihood of a False-Negative Finding on SLN Surgery in the 310 Women with cN1
Disease at Presentation, 2 or More SLNs Examined, and Residual Nodal Disease after Neoadjuvant
Chemotherapy
False-Negative SLN Findings FNR and 95% CI Fisher’s exact test p-value
Age
 18.0–49.9 years 20/150 13.3% (8.3–19.8%) 0.734
 50.0+ years 19/160 11.9% (7.3–17.9%)
Body mass index
 Overweight/obese (≥ 25.0) 25/227 11.0% (7.3–15.8%) 0.179
 Underweight/normal (< 25.0) 14/83 16.9% (9.5–26.7%)
cT category prior to chemotherapy
 Tis/T0/T1/T2 32/225 14.2% (9.9–19.5%) 0.182
 T3/T4 7/85 8.2% (3.4–16.2%)
Chemotherapy duration (months)
 4.0 or less 20/201 10.0% (6.2–15.0%) 0.073
 4.1 or more 19/109 17.4% (10.8–25.9%)
Palpable/fixed/matted Nodes after chemotherapy*
 yes 10/52 19.2% (9.6–32.5%) 0.166
 no 28/247 11.3% (7.7–16.0%)
Mapping agents used
 single 12/59 20.3% (11.0–32.8%) 0.052
 dual 27/251 10.8% (7.2–15.3%)
Multiple injection sites**
 yes 5/70 7.1% (2.4–15.9%) 0.206
 no 30/225 13.3% (9.2–18.5%)
Number of SLNs examined
 2 19/90 21.1% (13.2–31.0%) 0.007
 3 or more 20/220 9.1% (5.6–13.7%)
*
not reported in 11 patients
**
not reported in 15 patients
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